参考文献
［1］朱瑞森，余永利，陆汉魁，等.大剂量131I治疗312例分化型甲状腺癌转移灶的临床分析［J］.中华核医学与分子影像杂志，2002，22（6）：325-327.
［2］Smallridge RC，Copland JA. Anaplastic thyroid carcinoma：pathogenesis and emerging therapies［J］.Clinical Oncology，2010，22（6）：486-497.
［3］Sabra MM，Dominguez JM，Grewal RK，et al.Clinical outcomes and molecular profileofdifferentiated thyroid cancers with radioiodine-avid distant metastases［J］.J Clin Endocrinol Metab，2013，98（5）：E829-E836.
［4］Schlumberger M，Brose M，Elisei R，et al.Definition and management of radioactive iodine-refractory differentiated thyroid cancer［J］.Lancet Diabetes Endocrinol，2014，2（5）：356-358.
［5］Droz JP，Schlumberger M，Rougier P，et al. Chemotherapy in metastatic nonanaplastic thyroid cancer：experience at the Institut Gustave-Roussy［J］.Tumori，1990，76（5）：480-483.
［6］Drilon A，Laetsch TW，Kummar S，et al.Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children［J］.N Engl J Med，2018，378：731-739.(https://www.daowen.com)
［7］Spano JP，Vano Y，Vignot S，et al.GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma［J］. Med Oncol，2012，29（3）：1421-1428.
［8］Chen L，Shen Y，Luo Q，et al.Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroidcarcinoma［J］.Thyroid，2011，21（2）：119-124.
［9］王宇，渠宁，史潇，等.甲状腺髓样癌诊治现状及热点问题思考［J］.肿瘤预防与治疗，2019（6）：475-479.
［10］Hong DS，Cabanillas ME，Wheler J，et al.Inhibition of the Ras／Raf／MEK／ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies［J］.J Clin Endocrinol Metab，2011，96（4）：997-1005.
［11］Schlumberger M，Bastholt L，Dralle H，et al.2012 European thyroid association guidelines for metastatic medullary thyroid cancer［J］.European Thyroid Journal，2012，1（1）：5-14.
［12］Ravaud A，de la Fouchardiere C，Caron P，et al.A multicenter phaseⅡstudy of sunitinib in patients with locally advanced or metastatic differentiated，anaplastic or medullary thyroid carcinomas：mature data from the THYSU study［J］.Eur J Cancer，2017，76：110-117.